Live feed08:00:00·390dPRReleasevia QuantisnowENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 TrialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
